INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support

Neoplasia

Volumn 12, Issue 1, 2010, Pages 28-38

  Li, Jun ^a   Favata, Margaret ^a   Kelley, Jennifer A ^a   Caulder, Eian ^a   Thomas, Beth ^a   Wen, Xiaoming ^a   Sparks, Richard B ^a   Arvanitis, Ari ^a   Rogers, James D ^a   Combs, Andrew P ^a   Vaddi, Kris ^a   Solomon, Kimberly A ^a   Scherle, Peggy A ^a   Newton, Robert ^a   Fridman, Jordan S ^a  

^a Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BORTEZOMIB; CASPASE; DEXAMETHASONE; INCB 16562; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; MELPHALAN; PROTEIN MCL 1; STAT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL ACTIVITY; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR XENOGRAFT;

EID: 73949153879     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91192     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics. CA Cancer J Clin 58, 71-96.
2. Kyle RA and Rajkumar SV (2008). Multiple myeloma. Blood 111, 2962-2972.
3. Podar K, Chauhan D, and Anderson KC (2009). Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23, 10-24.
4. Zhang XG, Bataille R, Widjenes J, and Klein B (1992). Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 69, 1373-1376.
5. Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, and Poli V (1997). Defective development of pristane-oil - induced plasmacytomas in interleukin-6 - deficient BALB/c mice. Am J Pathol 151, 689-696.
6. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, and Kishimoto T (1992). Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 89, 232-235.
7. Kawano MM, Mihara K, Huang N, Tsujimoto T, and Kuramoto A (1995). Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 85, 487-494.
8. Klein B, Zhang XG, Lu ZY, and Bataille R (1995). Interleukin-6 in human multiple myeloma. Blood 85, 863-872.
9. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, and Epstein J (1994). Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84, 3063-3070.
10. Lichtenstein A, Tu Y, Fady C, Vescio R, and Berenson J (1995). Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162, 248-255.
11. Lichtenstein A, Berenson J, Norman D, Chang MP, and Carlile A (1989). Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74, 1266-1273.
12. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, and Anderson KC (1996). Multiple myeloma cell adhesion - induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87, 1104-1112.
13. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, and Anderson KC (1997). IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159, 2212-2221.
14. Berger LC, Hawley TS, Lust JA, Goldman SJ, and Hawley RG (1994). Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. Biochem Biophys Res Commun 202, 596-605.
15. Hideshima T, Bergsagel PL, Kuehl WM, and Anderson KC (2004). Advances in biology of multiple myeloma: clinical applications. Blood 104, 607-618.
16. Baker SJ, Rane SG, and Reddy EP (2007). Hematopoietic cytokine receptor signaling. Oncogene 26, 6724-6737.
17. Levine RL, Pardanani A, Tefferi A, and Gilliland DG (2007). Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7, 673-683.
18. Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, Alexander WS, Metcalf D, Hilton DJ, and Nicola NA (1999). Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J 18, 375-385.
19. Galm O, Yoshikawa H, Esteller M, Osieka R, and Herman JG (2003). SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101, 2784-2788.
20. Chim CS, Fung TK, Cheung WC, Liang R, and Kwong YL (2004). SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103, 4630-4635.
21. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, et al. (2001). Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15, 1950-1961.
22. Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, Podar K, Catley L, Hideshima T, Chauhan D, et al. (2009). Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 8, 26-35.
23. O'Shea JJ, Husa M, Li D, Hofmann SR, Watford W, Roberts JL, Buckley RH, Changelian P, and Candotti F (2004). Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 41, 727-737.
24. Burger R, Günther A, Bakker F, Schmalzing M, Bernand S, Baum W, Duerr B, Hocke GM, Steininger H, Gebhart E, et al. (2001). Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J 2, 42-53.
25. Gribble FM, Loussouarn G, Tucker SJ, Zhao C, Nichols CG, and Ashcroft FM (2000). A novel method for measurement of submembrane ATP concentration. J Biol Chem 275, 30046-30049.
26. Rawat R, Rainey GJ, Thompson CD, Frazier-Jessen MR, Brown RT, and Nordan RP (2000). Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. Blood 96, 3514-3521.
27. Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, and Gramatzki M (1998). Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 91, 1858-1863.
28. Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, and Bromberg J (2006). Pyridone 6, a pan-Janus - activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 66, 9714-9721.
29. Schwab G, Siegall CB, Aarden LA, Neckers LM, and Nordan RP (1991). Characterization of an interleukin-6 - mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 77, 587-593.
30. Puthier D, Bataille R, and Amiot M (1999). IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29, 3945-3950.
31. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, et al. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107, 351-362.
32. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, and Gores GJ (2005). Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42, 1329-1338.
33. Grigorieva I, Thomas X, and Epstein J (1998). The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 26, 597-603.
34. Dedera DA, Urashima M, Chauhan D, LeBrun DP, Bronson RT, and Anderson KC (1996). Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice. Br J Haematol 94, 53-61.
35. Bataille R, Jourdan M, Zhang XG, and Klein B (1989). Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84, 2008-2011.
36. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nuñez G, et al. (1999). Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115.
37. Quintanilla-Martinez L, Kremer M, Specht K, Calzada-Wack J, Nathrath M, Schaich R, Höfler H, and Fend F (2003). Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 162, 1449-1461.
38. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, et al. (2003). Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878.
39. Williams NK, Bamert RS, Patel R, Wang C, Walden PM, Wilks AF, Fantino E, Rossjohn J, and Lucet IS (2009). Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 387, 219-232.
40. Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, and Verstovsek S (2008). The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 99, 1265-1273.
41. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, et al. (2008). Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311-320.
42. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, and Tefferi A (2009). CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23, 1441-1445.